AgomAb Therapeutics N.V. American Depositary Shares Total Assets

AgomAb Therapeutics N.V. American Depositary Shares posts a total assets of $150M as of December 2025. That compares with $210M in the prior-year period — down 25.5% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, AgomAb Therapeutics N.V. American Depositary Shares's total assets was $210M. The latest reading is $150M — a 25.5% year-over-year decrease (period ending December 2025). Use the history and growth charts on this page for a longer lookback.

Total Assets is one piece of AgomAb Therapeutics N.V. American Depositary Shares's financial statement story. At $150M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for AGMB's total assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; AgomAb Therapeutics N.V. American Depositary Shares's other metric pages and overview cover the third.

Judging AgomAb Therapeutics N.V. American Depositary Shares against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in total assets easier to interpret. Start with $150M here, then scan peer and history charts to see if the gap is persistent.